RxDoctor Payments Data

Patrick Lopez

Family · Gilbert, AZNPI 1649876889

Payments from drug & device makers

$681in general payments, 2019–2025

Across 26 payments — averaging $26.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$346
  • Insulet Corporation$75
  • AbbVie$74
  • Boehringer Ingelheim$27
  • Lilly USA, LLC$27
  • Takeda Pharmaceuticals U.S.A., Inc.$27
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$681 in reported general payments places this provider in the 60th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$96,029
Medicare patients
283
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$53,375
OzempicSemaglutide46$49,651
JardianceEmpagliflozin23$26,956
TrulicityDulaglutide11$9,846
Levothyroxine Sodium263$2,590
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,514
Atorvastatin Calcium192$1,811
Azelastine Hcl60$1,625
Pantoprazole Sodium119$1,520
Albuterol Sulfate HfaAlbuterol Sulfate48$1,484
Gabapentin62$1,434
Metoprolol Succinate66$1,179
SynthroidLevothyroxine Sodium16$1,130
Omeprazole61$1,096
Rosuvastatin Calcium129$1,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$12$49,65146 claims
Boehringer IngelheimJardiance$27$26,95623 claims
Lilly USA, LLCTrulicity$27$9,84611 claims
AbbVieSynthroid$74$1,13016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,119 family providers in Arizona.

Other family in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →